This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down
by Zacks Equity Research
Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.
Tandem Diabetes Care, Inc. (TNDM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -17.39% and 3.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi
by Zacks Equity Research
Tandem's (TNDM) Mobi is claimed to be the world's smallest durable automated insulin delivery system.
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q4 Earnings Expected to Decline
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 20% and 3.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors remain optimistic about Tandem Diabetes (TNDM), backed by the impressive spree of product introductions.
Tandem Diabetes (TNDM) Avails Tandem Source in the United States
by Zacks Equity Research
Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.
Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.
Why Is Tandem Diabetes Care, Inc. (TNDM) Up 33.2% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.
Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View
by Zacks Equity Research
Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.
Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More
by Urmimala Biswas
MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.
Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra LifeSciences (IART) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of -2.56% and 1.35%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Soars 6.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View
by Zacks Equity Research
Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.
Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.